Evidence map›Paper›PMID 31111040›Full record

ReviewERJ open research2019

From the pathophysiology of the human lung alveolus to epigenetic editing: Congress 2018 highlights from ERS Assembly 3 "Basic and Translational Science."

Marko Z Nikolić, Eva M Garrido-Martin, Flavia R Greiffo, Aurélie Fabre, Irene H Heijink, Agnes Boots, Catherine M Greene, Pieter S Hiemstra, Sabine Bartel

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ERJ open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 5 countries.

Marko Z NikolićUniversity College London, Division of Medicine, London, UK.ORCID https://orcid.org/0000-0001-6304-6848
Eva M Garrido-MartinH12O-CNIO Lung Cancer Clinical Research Unit, Research Institute Hospital 12 Octubre - Spanish National Cancer Research Centre (CNIO), and Biomedical Research Networking Centre Consortium of Cancer (CIBERONC), Madrid, Spain.
Flavia R GreiffoComprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München; Member of the German Center for Lung Research (DZL), Munich, Germany.
Aurélie FabreUniversity College Dublin, St Vincent's University Hospital, Elm Park, Dublin, Ireland.
Irene H HeijinkUniversity of Groningen, University Medical Center Groningen, Depts of Pathology and Medical Biology and Pulmonology, GRIAC Research Institute, Groningen, The Netherlands.
Agnes BootsDept of Pharmacology and Toxicology, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Catherine M GreeneLung Biology Group, Dept of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
Pieter S HiemstraDept of Pulmonology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-0238-5982
Sabine BartelEarly Life Origins of Chronic Lung Disease, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, Germany.ORCID https://orcid.org/0000-0002-9163-795X
Helmholtz Zentrum München · DELeiden University Medical Center · NLMaastricht University · NLResearch Center Borstel - Leibniz Lung Center · DERoyal College of Surgeons in Ireland · IESpanish National Cancer Research Centre · ESUniversity College Dublin · IEUniversity College London · GBUniversity Medical Center Groningen · NL

Funding

Medical Research Council MR/S005579/1
6 · The paper itself

Abstract

The European Respiratory Society (ERS) International Congress is the largest respiratory congress and brings together leading experts in all fields of respiratory medicine and research. ERS Assembly 3 shapes the basic and translational science aspects of this congress, aiming to combine cutting-edge novel developments in basic research with novel clinical findings. In this article, we summarise a selection of the scientific highlights from the perspective of the three groups within Assembly 3. In particular, we discuss new insights into the pathophysiology of the human alveolus, novel tools in organoid development and (epi)genome editing, as well as insights from the presented abstracts on novel therapeutic targets being identified for idiopathic pulmonary fibrosis.

Identifiers

PMID31111040
PMCPMC6513036
OpenAlexW2945873825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.